crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Pre-Mkt 01-23 06:50:47 EST

208.39

-1.84

-0.88%

High214.31	Low207.91	Vol258.27K
Open211.00	D1 Closing210.23	Amplitude3.05%
Mkt Cap12.00B	Tradable Cap10.16B	Total Shares57.60M
T/O54.03M	T/O Rate0.53%	Tradable Shares48.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":208.39,"timestamp":1769115600000,"preClose":210.23,"halted":0,"volume":258270,"delay":0,"changeRate":-0.008752318888836054,"floatShares":48764858,"shares":57596887,"eps":6.247815,"marketStatus":"Pre-Mkt","change":-1.84,"latestTime":"01-23 06:50:47 EST","open":211,"high":214.31,"low":207.905,"amount":54026119.5555,"amplitude":0.030467,"askPrice":331.33,"askSize":21,"bidPrice":206.73,"bidSize":7,"shortable":3,"etf":0,"ttmEps":6.247815,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769178600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":208.39,"dividendRate":0.004295,"postHourTrading":{"tag":"盘后","latestPrice":208.39,"preClose":208.39,"latestTime":"19:59 EST","volume":9263,"amount":1930392.96,"timestamp":1769129981925,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9106590159500061,"impliedVol":0.3104,"impliedVolPercentile":0.404},"requestUrl":"/m/hq/s/CR/wiki","defaultTab":"wiki","newsList":[{"id":"1133302044","title":"Earning Preview: crane’s revenue is expected to increase by 7.13%, and institutional views are constructive","url":"https://stock-news.laohu8.com/highlight/detail?id=1133302044","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1133302044?lang=en_us&edition=fundamental","pubTime":"2026-01-19 10:33","pubTimestamp":1768790002,"startTime":"0","endTime":"0","summary":"Abstract Crane Company will report fourth-quarter results on January 26, 2026 Post Market; our preview consolidates management’s latest guidance and external estimates to frame expectations for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: crane’s revenue is expected to increase by 7.13%, and institutional views are constructive","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR"],"gpt_icon":0},{"id":"2605051451","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2605051451","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605051451?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:00","pubTimestamp":1768993200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Ally Fincl Inc                                  4Q      1.02   7:30 AM. ·Banc of California                              4Q       .37   4:15 PM. ·Johnson & Johnson                                4Q      2.46   6:45 AM. ·Live Oak Bncshrs                                 4Q       .56   4:30 PM. ·Old Natl Bancorp                                 4Q       .59   7:00 AM. ·TE Connectivity plc                              1Q      2.54   6:00 AM. ·Travelers Cos Inc.                               4Q      8.77   6:57 AM. ·Alaska Air Grp Inc.                              4Q       .11       AMC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5d43aa795981e6ad85d125e1c14e8693","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLB","CSX","BFST","BRO","JNJ","CMA","AA","EGBN","BCML","INTC","EQBK","CUBI","AMTB","ERIC","ISRG","ACNB","MKC","AGNC","BHRB","EBC","BMRC","BKR","CATY","COF","BOH","CVRX","CACI","ABT","MOG.B","ARE","CFG","ASB","EFSC","DCOM","ALK","GE","HAL","BAH","AUB","BANR","CARE","BY","BKU","PG","CADE","CR","ALLY","COLB","BANC","AGYS"],"gpt_icon":1},{"id":"2603966762","title":"How Crane’s Q3 Beat And Operational Discipline At Crane (CR) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2603966762","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603966762?lang=en_us&edition=fundamental","pubTime":"2026-01-16 16:17","pubTimestamp":1768551450,"startTime":"0","endTime":"0","summary":"Crane Company recently presented at CJS Securities’ 26th Annual “New Ideas for the New Year” Investor Conference on 14 January 2026, following a third-quarter revenue increase of 7.5% year on year that surpassed analyst expectations by 1.6%.\nThe company pointed to its differentiated technology portfolio, focus on commercial excellence, and disciplined operations as central to its stronger-than-expected quarterly performance, reinforcing its positioning across critical aerospace, electronics,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/how-cranes-q3-beat-and-operational-discipline-at-crane-cr-ha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/how-cranes-q3-beat-and-operational-discipline-at-crane-cr-ha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","LU2264538146.SGD","LU2430703095.HKD","IE00BKVL7J92.USD","IE00BHPRN162.USD","LU1670627923.USD","CRS","LU0417517546.SGD","BK4534","LU0106831901.USD","LU0787776722.HKD","LU1244550494.USD","ACR.AU","LU0820561818.USD","LU0943347566.SGD","LU0170899867.USD","LU2106854487.HKD","CRS.AU","LU0683600562.USD","LU0251132253.USD","CR","LU0106261372.USD","LU0211328371.USD","IE00BFXG1179.USD","LU1064131342.USD","LU0820562030.AUD","LU0345770308.USD","LU1629891620.HKD","LU0006306889.USD","LU0208291251.USD","LU2023250843.SGD","LU2756315664.SGD","LU1974910355.USD","ORR.AU","LU0345769631.USD","LU0345770993.USD","LU2065731478.USD","LU2746668461.USD","LU0868494617.USD","LU1084165304.USD","IE00B3S45H60.SGD","ORR","IE0034235295.USD","ACR","IND","BK4581","IE0034235188.USD","BK7508","IE00BN8TJ469.HKD"],"gpt_icon":0},{"id":"2602554352","title":"Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2602554352","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602554352?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:36","pubTimestamp":1768224960,"startTime":"0","endTime":"0","summary":"– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan.  12, 2026  (GLOBE NEWSWI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216928/0/en/Moleculin-Accelerates-Outlook-Into-2026-With-First-Pivotal-Trial-Unblinding-on-Track-Global-Trial-Expansion-and-Multiple-Externally-IIT-Funded-Clinical-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2602702514","title":"Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2602702514","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602702514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219200,"startTime":"0","endTime":"0","summary":"FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216717/0/en/Relmada-Therapeutics-Provides-Regulatory-Update-Confirming-FDA-Alignment-on-Registrational-Studies-Design-for-NDV-01-for-Two-Separate-Indications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFS","BK4161","LU1861220207.SGD","BK4166","BK4588","BK4139","BK4007","LU0106831901.USD","CR","LU1861217088.USD","LENZ","LU2360107671.USD","BK4539","BK4585","LU1668664300.SGD","LU1791807156.HKD"],"gpt_icon":0},{"id":"2602514492","title":"Press Release: Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514492","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514492?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219200,"startTime":"0","endTime":"0","summary":"-- Approximately $44 million and $125 million in preliminary  Revuforj  4Q25 and full year 2025 net revenue, respectively --. -- Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs. 3Q25 -. -- $56 million and $152 million in preliminary  Niktimvo  4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results --. -- Ended 2025 with approximately $394 million in cash, cash equivalents and marketable securities ; fully funded through profitability --. NEW YORK, Jan. 12, 2026  -- Syndax Pharmaceuticals , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced preliminary, unaudited fourth quarter and full year 2025 financial results and provided additional business updates ahead of its presentation at the 44 Annual J.P. Morgan Healthcare conference.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LU0882574139.USD","LU1720051108.HKD","LU1791710400.SGD","LU1732800096.USD","LU1363072403.SGD","LU0106261372.USD","HCSG","LU0234570918.USD","LU2023251221.USD","XBI","XLV","LU0320765646.SGD","LU1732799900.SGD","IE00BZ1G4Q59.USD","TM","LU1791710582.SGD","BK4137","LU0029874061.USD","LU1244550494.USD","LU0225283273.USD","BK4581","LU2111349929.HKD","BK4555","R","BK4504","LU1989772923.USD","BK4588","BK4516","LU2089283258.USD","LU1244550577.SGD","LU2271345857.HKD","LU0557290698.USD","BK4139","CR","LU1720051017.SGD","BK4534","BK4604","IE00BKVL7J92.USD","LABU","LU0158827948.USD","LU0098860793.USD","LU1244550221.USD","LU0158827781.USD","LU0528227936.USD","03160","LU0314104364.USD","SNDX","LU2089284900.SGD"],"gpt_icon":0},{"id":"2601870204","title":"BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2601870204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601870204?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787200,"startTime":"0","endTime":"0","summary":"BBO-8520 monotherapy in patients withKRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients elig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214384/0/en/BBOT-Announces-New-Clinical-Data-Advancing-Its-Portfolio-of-Three-Innovative-and-Differentiated-RAS-and-PI3K%CE%B1-Pipeline-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOC","BK4161","BK4195","BK4211","CR","BK4590","LU0456854461.SGD","ORR","CRC","BK4190","ET","BK4213","BK4588","LU0266512127.USD","BK4218","BK4585","BK4144","BK4581","BK4181","PFS","PK","BC","BK4139","PR","BK4561","BBOT"],"gpt_icon":0},{"id":"1167800141","title":"CR CONSTRUCTION (01582): Winding-Up Order Against CR Sea Has Been Terminated","url":"https://stock-news.laohu8.com/highlight/detail?id=1167800141","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167800141?lang=en_us&edition=fundamental","pubTime":"2026-01-07 19:32","pubTimestamp":1767785535,"startTime":"0","endTime":"0","summary":"CR CONSTRUCTION (01582) announced an update regarding the winding-up order issued by the court on October 14, 2025, against CR Sea, an indirect wholly-owned subsidiary of the company. The court...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1148","BK4161","CR","01582"],"gpt_icon":0},{"id":"2601818471","title":"Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818471","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818471?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:45","pubTimestamp":1767707100,"startTime":"0","endTime":"0","summary":"Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213650/0/en/Actuate-Therapeutics-Announces-Positive-Patient-Outcomes-from-Phase-1-Trial-in-Difficult-to-Treat-Refractory-Pediatric-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211817866.USD","LU2413666426.HKD","BK4548","LU0347712357.USD","CNS","ACTU","BK4213","BK4139","BK4121","BK4135","IE00BYQQ9H92.USD","LU1721428933.USD","BK4161","PR","LU1093756325.SGD","BK4567","LU1093756168.USD","ETS","BK4585","BK4232","MTD","BK4588","IE00B5TLWC47.USD","SD","CR","IE00BFXG0V08.USD","EWS","LU2413666699.HKD","BK4533"],"gpt_icon":0},{"id":"2601289287","title":"NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601289287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601289287?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700800,"startTime":"0","endTime":"0","summary":"Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213445/0/en/NovaBridge-Presents-Positive-Givastomig-Dose-Expansion-Data-from-the-Phase-1b-Combination-Study-in-Patients-with-1L-Metastatic-Gastric-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4195","PD","BK4023","BK4211","CR","PR","LU1169589451.USD","SD","LU1169590202.USD","IHC","BK4161","BK4218","PK","BK4213","PFS","BK4162"],"gpt_icon":0},{"id":"2601882111","title":"BRIEF-Crane Company Completes Acquisition Of Precision Sensors & Instrumentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882111","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882111?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:11","pubTimestamp":1767622274,"startTime":"0","endTime":"0","summary":"BRIEF-Crane Company Completes Acquisition Of Precision Sensors & Instrumentation Jan 5 (Reuters) - Crane Co CR.N:CRANE COMPANY COMPLETES ACQUISITION OF PRECISION SENSORS & INSTRUMENTATION AND ANNOUNCE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUALCNJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2601889844","title":"Baker Hughes Closes Sale of Precision Sensors & Instrumentation to Crane Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889844?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:35","pubTimestamp":1767616513,"startTime":"0","endTime":"0","summary":"Baker Hughes has completed the sale of its Precision Sensors & Instrumentation  product line to Crane Company for $1.15 billion in cash before customary closing adjustments. The PSI business includes the Druck, Panametrics, and Reuter-Stokes brands. The transaction, originally announced in July 2025, is part of Baker Hughes’ strategy to enhance its balance sheet and redeploy capital toward higher-return opportunities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baker Hughes Company published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbyssYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","LU0251131958.USD","LU1917777945.USD","BKR","LU0048573561.USD","LU2210150020.SGD","CR","IE00B19Z3B42.SGD","LU0314104364.USD","LU1153585028.USD","LU2023250504.SGD","SG9999014005.SGD","LU2106854487.HKD","LU1119994496.HKD","LU1974910355.USD","SG9999014013.SGD","LU0154245756.USD","LU0256331488.USD","LU2463526074.USD","LU2023250843.SGD","IE00B64PRP62.GBP","IE0002270589.USD","LU1261432733.SGD","BK4585","LU2095319765.USD","LU0742534661.SGD","IE00BGHQF748.EUR","BK4161","LU0011850046.USD","LU2210149790.SGD","IE00BKPKM429.USD","LU1084165304.USD","IE00B3QW5Z07.USD","BK4588","NDAQ","BK4112","LU0211331839.USD","BK4566","SG9999014021.USD","IE00B19Z3581.USD","BK4179","LU0154245673.USD","SG9999014039.USD","LU0251142724.SGD"],"gpt_icon":0},{"id":"2601889884","title":"Crane Company Publishes Update to Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889884","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889884?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:31","pubTimestamp":1767616260,"startTime":"0","endTime":"0","summary":"Crane Company will release its fourth quarter 2025 earnings on January 26, 2026, after the close of market, with results available by public distribution and on the Crane Company website at www.craneco.com. A teleconference to discuss the results, hosted by Max H. Mitchell , Alex Alcala , and Richard A. Maue , is scheduled for January 27, 2026, at 10:00 AM  and can be accessed in listen-only mode via the Company’s website at www.craneco.com. An accompanying slide presentation will also be available on the same site. A web replay will be available shortly after the call’s completion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via Business Wire  on January ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL2jWKSD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2601886048","title":"Crane Company Completes Acquisition of Precision Sensors & Instrumentation and Announces Date for Fourth Quarter 2025 Earnings Release and Teleconference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886048?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:30","pubTimestamp":1767616200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUALCNJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2593583224","title":"Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583224","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583224?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":"Completed enrollment in LEGEND's pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ. Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol. enGene selected for FDA's CDRP Program to support CMC readiness. Cash and marketable securities plus proceeds from November financing expected to provide cash runway into 2H 2028. \"We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved,\" said Ron Cooper, President and Chief Executive Officer. \"With recent acceptance into FDA's CDRP program and a cash position of $342.4 million, extending our runway into the second half of 2028, we are entering the new year laser-focused on scaling our organization in prepar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","IE00B1BXHZ80.USD","CR","LU2237443622.USD","LU2237443382.USD","BCG","ENGN","IE00BKVL7J92.USD","LU0149725797.USD","BK4006","CMC","LU0170899867.USD","LU2237443978.SGD","LU2237443465.HKD","BK4232","BK4022","LU2237443549.SGD","LU2237443895.HKD","LU2746668974.SGD","LU1363072403.SGD","TRAE","IE00BFXG1179.USD","IE00BZ1G4Q59.USD","LU2746668461.USD","BK4161","LU0882574139.USD","BK4135","DDX","LU0971096721.USD","LU0267386448.USD","BK4139","IE00BHPRN162.USD"],"gpt_icon":0},{"id":"2593048418","title":"Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor","url":"https://stock-news.laohu8.com/highlight/detail?id=2593048418","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593048418?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:29","pubTimestamp":1766402940,"startTime":"0","endTime":"0","summary":"Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically dev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/22/3209070/0/en/Abbisko-Therapeutics-CSF-1R-Inhibitor-Pimicotinib-Approved-by-the-China-NMPA-Addressing-the-Treatment-Gap-for-Tenosynovial-Giant-Cell-Tumor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ORR","CR","BK4539","BK4161","BK4139","BK4081","CSF","EMA","BK4007"],"gpt_icon":0},{"id":"1131050199","title":"CR Construction (01582): CR Sea to Strive for Termination Ruling at January 7, 2026 Hearing","url":"https://stock-news.laohu8.com/highlight/detail?id=1131050199","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131050199?lang=en_us&edition=fundamental","pubTime":"2025-12-18 17:20","pubTimestamp":1766049639,"startTime":"0","endTime":"0","summary":"CR Construction (01582) announced that its indirect wholly-owned subsidiary, CR Sea (Malaysia) Sdn. Bhd. (CR Sea), received a winding-up petition dated May 27, 2025, on May 30, 2025, concerning an...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1148","BK4161","CR","01582"],"gpt_icon":0},{"id":"2590326220","title":"Why Is Gene Therapy Focused Senti Bio Stock Falling Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590326220","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590326220?lang=en_us&edition=fundamental","pubTime":"2025-12-10 02:34","pubTimestamp":1765305240,"startTime":"0","endTime":"0","summary":"Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable remissions, and a favorable safety profile.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","ASH","SNTI","BK4539","CR","ORR","BK4161","LU2463526074.USD","BK4109"],"gpt_icon":0},{"id":"2590343065","title":"Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343065","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343065?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281600,"startTime":"0","endTime":"0","summary":"ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202225/0/en/Senti-Bio-Announces-Updated-SENTI-202-Clinical-Data-from-Ongoing-Phase-1-Trial-in-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-Patients-Demonstrating-Deep-MRD-Negative-Durable-Com.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0347712357.USD","LU1721428933.USD","LU2413666426.HKD","BK4024","LU2413666699.HKD","BK4585","BK4121","BK4109","ORR","LU1093756168.USD","IE0009354923.USD","BK4548","ASH","MTD","BK4563","BK4533","BK4183","LU2211817866.USD","BK4567","IE00BFXG0V08.USD","BK4588","BK4161","AEI","IE00BYQQ9H92.USD","LD","LU1093756325.SGD","ODD","CR","LU2463526074.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cranenxt.com","stockEarnings":[{"period":"1week","weight":0.0072},{"period":"1month","weight":0.1027},{"period":"3month","weight":0.0867},{"period":"6month","weight":0.0926},{"period":"1year","weight":0.2874},{"period":"ytd","weight":0.1299}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.023863},{"month":2,"riseRate":0.711111,"avgChangeRate":0.035546},{"month":3,"riseRate":0.577778,"avgChangeRate":0.017327},{"month":4,"riseRate":0.608696,"avgChangeRate":0.002531},{"month":5,"riseRate":0.630435,"avgChangeRate":0.008709},{"month":6,"riseRate":0.586957,"avgChangeRate":0.005131},{"month":7,"riseRate":0.586957,"avgChangeRate":0.004401},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.009516},{"month":9,"riseRate":0.369565,"avgChangeRate":-0.022666},{"month":10,"riseRate":0.586957,"avgChangeRate":0.009396},{"month":11,"riseRate":0.543478,"avgChangeRate":0.025826},{"month":12,"riseRate":0.608696,"avgChangeRate":0.018097}],"exchange":"ARCA","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction